<DOC>
	<DOCNO>NCT02977754</DOCNO>
	<brief_summary>The principal objective study explore role 18F-FDG PET identify sorafenib-induced metabolic shift HCC , thus predict treatment response disease outcome advance HCC patient candidate systemic treatment sorafenib .</brief_summary>
	<brief_title>18F-FDG PET HCC Patients Candidate Treatment With Sorafenib</brief_title>
	<detailed_description>Aerobic glycolysis also call `` Warburg effect '' , represent one distinctive hallmark malignant cell . Although energetically less efficient respiration , fermentative metabolism advantageous cell growth due increase availability anabolic intermediate reduce cell dependence oxygen . Moreover , increase intracellular reduce equivalent decrease mitochondria-derived ROS , glycolysis protects malignant cell oxidant-induced senescence apoptosis . In diagnostic imaging , `` Warburg effect '' visualize thanks utilization ﬂuoro-2-deoxyglucose , glucose analogue , label positron emit nuclide fluoride-18 ( 18F ) . F-2-ﬂuoro-2-deoxyglucose ( 18F-FDG ) positron emission tomography ( PET ) emerge useful many tumor type HCC help rule extra-hepatic metastasis sit recurrent disease , give prognostic information . Considering abovementioned premise , investigator hypothesize potential use 18F-FDG PET early assessment sorafenib-induced metabolic shift HCC , especially well-differentiated subtypes usually show uptake tracer different least sufficiently increase compare normal liver . For reason investigator decide conduct explorative study assessment predictive prognostic role 18F-FDG PET patient affect advanced HCC candidate systemic treatment sorafenib . The principal objective study explore role 18F-FDG PET identify sorafenib-induced metabolic shift HCC , thus predict treatment response disease outcome advance HCC patient candidate systemic treatment sorafenib . More specifically investigator : - compare 18F-FDG uptake HCC lesion , identify target lesion ( diam . min . 2cm ) , baseline , 24 hour 1 week first administration sorafenib . - correlate pattern 18F-FDG uptake HCC lesion objective tumor response assess 8 week first administration sorafenib accord mRECIST criterion . - correlate pattern 18F-FDG uptake HCC lesion alpha-fetoprotein ( AFP ) variation baseline , 24 hour 1 week first administration sorafenib . - correlate pattern 18F-FDG uptake HCC lesion progression-free survival ( PFS ) overall survival ( OS ) .</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>patient histological diagnosis HCC schedule undergo systemic treatment sorafenib ; obtain informed consent patient age &lt; 18 year pregnancy breastfeeding ; patient affect malignancy within last 3 year , exception surgically cure carcinoma situ cervix , situ breast cancer , incidental finding stage T1a T1b prostate cancer , basal/squamous cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>